Navigation Links
Pluromed Announces Completion of Enrollment in LeGoo™ Cardiac Bypass Clinical Trial

Pluromed, Inc. has completed enrollment in its LeGoo™ off-pump coronary artery bypass clinical study, based on a protocol reviewed by the U.S. Food and Drug Administration (FDA). When completed, the report of the study will be filed with the FDA as part of the company's submission for U.S. regulatory approval of LeGoo™.

(PRWEB) -- Pluromed, Inc. today announced that it has completed enrollment in its LeGoo™ off-pump coronary artery bypass clinical study, which is evaluating the clinical efficacy of LeGoo™ as compared to a traditional vessel loop. This prospective, randomized trial commenced enrollment in 2008 and has reached its goal of 110 patients, enrolled at 9 hospitals in 4 countries. Principal investigators for the trial were Gerhard Wimmer-Greinecker, M.D., Ph.D., Ardawan Rastan, M.D., Ph.D., Volkmar Falk, M.D., PhD, Olivier Bouchot, M.D., Jan Gummert, M.D., Ph.D., Jean-Philippe Verhoye, M.D., Ph.D., Louis Perrault, M.D., Ph.D., Anno Diegeler, M.D., Ph.D. and Jos G. Maessen, M.D., Ph.D.; Dr. Valavanur A. Subramanian, Chairman of the Department of Cardiothoracic Surgery at The Lenox Hill Heart and Vascular Institute of New-York, served as Chairman of the study’s Data Safety Monitoring Board.

Pluromed’s LeGoo™ is a polymer-based device which is comprised of a non-toxic and biocompatible gel that exists as a liquid at low temperatures and rapidly transitions to a solid at body temperature, forming a plug that can occlude blood vessels. LeGoo™ is injected into a blood vessel that is intended to be occluded, where it stays in a “plug” form for several minutes allowing the surgeon to work in a bloodless field. The gel dissolves with time (spontaneously) or can be reversed back to liquid instantly by cooling the site with ice or irrigating with cold saline. Once dissolved below a minimum concentration, the polymer cannot never re-solidify.

The primary purpose of the study is to demonstrate the clinical safety and efficacy of LeGoo™ in comparison to a standard vessel occlusion method (i.e. vessel loops). Although LeGoo™ is also designed for use in other vascular surgeries where temporary vessel occlusion is desired, this study specifically focuses on the use of LeGoo™ in off-pump coronary bypass (OPCAB, as a most sensitive model of adverse changes that may occur at any vascular site outside of the neurovascular system. The primary endpoint is the proportion of anastomoses (process of suturing the bypass graft to the coronary artery) in which satisfactory hemostasis is achieved.

Dr. William J Cohn, Director of Minimally Invasive Technology at Texas Heart Institute, is the medical director of the study. "With enrollment completed, our focus now turns to data monitoring, completion of follow up and preparation for filing with the U.S. Food and Drug Administration and for primary endpoint publication” said Dr. Cohn. "We are grateful to all the trial investigators who have worked so diligently to reach this milestone."

“This important trial is the latest example of the commitment of leading vascular and cardiovascular surgeons, who seek less traumatic methods to improve patient outcome”, said Jean-Marie Vogel, President and CEO of Pluromed. “We appreciate the participation of the 22 leading physicians and 13 research coordinators, whose efforts led to the successful completion of enrollment."

About Pluromed, Inc.
Pluromed, Inc., Woburn, Massachusetts, founded in 2003, is pioneering the use of atraumatic gel plugs to improve the safety, efficacy and economics of medical interventions. These products potentially address a broad surgery market that includes cardiac and vascular surgery, prostate, kidney and liver surgery, plastic/reconstructive surgery, trauma/battlefield applications and the treatment of kidney stones. They are based on the Company's patented rapid phase transition polymer technology; Pluromed Rapid Transition PolymersÔ (RTP™) are liquid at low temperature and quickly transition to a high viscosity gel at body temperature. Pluromed’s BackStop™, a product used in the treatment of ureteral stones, is cleared for human use in Europe, Canada and the United States. LeGoo™is approved for human use in Europe but is not currently cleared for human use in the USA. For more information, please visit


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. Pluromed, Inc. Signs Agreement with Boston Scientific
2. Nuvo Research announces early redemption of 5% convertible debentures
3. Good Vibrations Announces Enhanced Education Program
4. Young Innovations, Inc. Announces Record EPS for the Year
5. TeamHealth Holdings, Inc. Announces Fourth Quarter and Full Fiscal 2009 Earnings Release Date and Conference Call
6. Sunquest Announces Significant Speaker Schedule for HIMSS 2010
7. Announces the Addition of Fully Accredited Law and Criminal Justice Degree Programs to its Current Website Offerings
8. Announces Expansion of Liberal Arts & Humanities to its Accredited Online Degree Programs
9. Sinovac Announces Closing of Common Share Offering
10. WellPoint Announces Appearance at Upcoming Conference
11. Healthcare Realty Trust Announces Fourth Quarter Dividend
Post Your Comments:
(Date:6/25/2016)... ... , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors ... Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green ... hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Collagen Matrix, Inc., ("Collagen ... and manufacturing of collagen and mineral based medical ... that Bill Messer has joined the ... further leverage the growing portfolio of oral surgery, ... Bill joins the Collagen Matrix executive team ...
(Date:6/24/2016)... 24, 2016 Research and ... "Structural Electronics 2015-2025: Applications, Technologies, Forecasts" report ... In-Mold Electronics, Smart Skin, Structural Health Monitoring, ... Structural electronics involves electronic and/or electrical components ... replacing dumb structures such as vehicle bodies or ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
Breaking Medicine Technology: